|
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin Efficacy International Trial
Ongoing trial
 |
Author(s) |
Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, McCrary Sisk C, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM |
 |
Title(s) |
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes |
|
Reference(s) |
Am Heart J 2008;156:826–32 |
|
Disease |
Acute coronary syndromes |
|
Purpose |
To examine whether the combination of ezetimibe plus simvastatin can increase clinical benefit on cardiovascular outcomes compared to simvastatin monotherapy in patients stabilised after acute coronary syndromes |
|
Study design |
Randomised, double-blind, controlled |
|
Follow-up |
Aim 2.5 years |
|
Patients |
Aim 18,000 patients, recently hospitalised for ST-segment elevation MI, non-ST-segment elevation MI or unstable angina pectoris and stabilised for at least 24 h, with LDL cholesterol 50–125 mg/dl for those not receiving lipid-lowering therapy and 50–100 mg/dl for those receiving chronic statin therapy |
|
Treatment regimen |
Simvastatin, 40 mg/day titrated to 80 mg/day if LDL cholesterol > 79 mg/dl, alone or in combination with ezetimibe, 10 mg/day |
|
Results |
Not yet available |
|
|
|
